Brind.

FDA approved UroGen Pharma Ltd.'s second product for bladder cancer, which the company has operations in Israel.

Steady: 1 in the last 7 days Updated wednesday

The latest in this situation

ZUSDURI reported $68M revenue and FDA accepted NDA for UGN-103.Wednesday

How it started

2 reports, 1 independent, last reported Aug 21. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA approved UroGen Pharma Ltd.'s second product for bladder cancer, which the company has operations in Israel.

Who's involved

What this event is mainly about

FDA

How it developed

Newest first. Tap a step to see who reported it.

Jun 8FDA approved ZUSDURI, an innovative formulation of mitomycin, for bladder cancer.Sub-event
Aug 21UroGen Pharma Ltd. received FDA approval for a bladder cancer product.1 source
- GlobeNewswire

Keep exploring

The entities involved

FDA
- The FDA approved Miplyffa for the treatment of Niemann-Pick disease.00:55
- iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Fri 23:50

Coverage

Newest first; wire copies grouped

Aug 21GlobeNewswireUroGen Pharma to Present at Upcoming Investor Conferences PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercia
Jul 29GlobeNewswireUroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July